Skip to content
HowShorted

AnaptysBio, Inc. short interest in 2023

In 2023, AnaptysBio, Inc.'s disclosed short interest ran from 17.39% of shares outstanding on 13 Jan 2023 to 16.81% on 29 Dec 2023, a change of -0.58 percentage points. The year's high was 19.02% on 31 Oct 2023 and its low 14.76% on 31 Jan 2023, averaging 17.13% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 34.42 days on 31 May 2023. Full history: AnaptysBio, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for AnaptysBio, Inc. in 2023

2023 in figures

Start of year
17.39% (13 Jan 2023)
End of year
16.81% (29 Dec 2023)
Change
-0.58 pp
High
19.02% (31 Oct 2023)
Low
14.76% (31 Jan 2023)
Average
17.13%
Highest days to cover
34.42 (31 May 2023)
SEC filings marked
9

Every report in 2023

AnaptysBio, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202317.39%10.01results (8-K)
31 Jan 202314.76%7.35
15 Feb 202314.84%22.71
28 Feb 202315.31%18.24
15 Mar 202316.44%22.7610-K filed, results (8-K)
31 Mar 202316.86%21.10
14 Apr 202317.05%17.89
28 Apr 202317.11%20.35
15 May 202317.35%26.8310-Q filed, results (8-K)
31 May 202317.79%34.42
15 Jun 202316.85%27.43
30 Jun 202316.56%15.99
14 Jul 202316.46%31.84
31 Jul 202316.70%21.16
15 Aug 202317.79%12.7310-Q filed, results (8-K)
31 Aug 202317.47%20.42
15 Sep 202317.66%15.34
29 Sep 202317.86%16.15
13 Oct 202318.68%24.89
31 Oct 202319.02%23.83
15 Nov 202318.60%20.5010-Q filed, results (8-K)
30 Nov 202318.70%29.37
15 Dec 202316.94%12.12
29 Dec 202316.81%22.37

See also: AnaptysBio, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.